Vantage logo

Novartis trims its pipeline

Discontinuations for branaplam, iptacopan and Piqray could increase pipeline scepticism, but more pruning is coming.

Vantage logo

Fate runs out of excuses

The plug is pulled on a deal with J&J, and Fate swings the axe over its staff and NK cell pipeline.

Vantage logo

Your 2023 wildcard predictions revealed

Will biotech lead a bull market recovery? Will Novartis spin off its cell therapy business? Read on for some of your leftfield predictions for biopharma.

Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.